Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis

被引：0
|
作者：
Zhong, Xinxin [1 ]
Lin, Ao [2 ]
Luo, Jian [1 ]
Li, Yeqin [1 ]
Chen, Jinlan [1 ]
Ning, Chao [1 ]
Cao, Fu [1 ,3 ]
机构：
[1] Red Cross Hosp Yulin City, Dept Pulm & Crit Care Med, Yulin 537000, Guangxi, Peoples R China
[2] Red Cross Hosp Yulin City, Dept Cardiothorac Surg, Yulin 537000, Guangxi, Peoples R China
[3] Red Cross Hosp Yulin City, Dept Pulm & Crit Care Med, 1 Jinwang Rd, Yulin 537000, Guangxi, Peoples R China
来源：
POSTGRADUATE MEDICAL JOURNAL | 2024年 / 100卷 / 1184期
关键词：
antituberculosis drugs; multidrug-resistance; mycobacterium; chemotherapy; MYCOBACTERIUM-TUBERCULOSIS; BACTERICIDAL ACTIVITY; IN-VITRO; MDR-TB; BEDAQUILINE; REGIMENS; PRETOMANID; DISCOVERY; DELAMANID; EFFICACY;
D O I：
10.1093/postmj/qgad140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multidrug-resistant tuberculosis (MDR-TB) has become a critical challenge to public health, and the prevention and treatment of MDR-TB are of great significance in reducing the global burden of tuberculosis. How to improve the effectiveness and safety of chemotherapy for MDR-TB is a pressing issue that needs to be addressed in tuberculosis control efforts. This article provides a comprehensive review of the clinical application of new antituberculosis drugs in MDR-TB, aiming to provide a scientific basis for the prevention and treatment strategy of MDR-TB.
引用
收藏
页码：366 / 372
页数：7
相关论文
共 50 条
  • [1] Novel treatments in multidrug-resistant tuberculosis
    Mondoni, Michele
    Saderi, Laura
    Sotgiu, Giovanni
    CURRENT OPINION IN PHARMACOLOGY, 2021, 59 : 103 - 115
  • [2] A breakthrough in the treatment of multidrug-resistant tuberculosis: A novel and effective approach
    Pardeshi, Vaishali
    Lokhande, Tushar
    Shelke, Ashwini
    Tuse, Trupti
    Pawar, Bhagyshree
    Bonde, Chandrakant
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2022, 71 (04): : 413 - 423
  • [3] Pharmacokinetics of Second-Line Antituberculosis Drugs in Children with Multidrug-Resistant Tuberculosis in India
    Kumar, Agibothu Kupparam Hemanth
    Kumar, Alok
    Kannan, Thiruvengadam
    Bhatia, Rakesh
    Agarwal, Dipti
    Kumar, Santosh
    Dayal, Rajeshwar
    Singh, Sheo Pratap
    Ramachandran, Geetha
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
  • [4] Delamanid in the treatment of multidrug-resistant tuberculosis
    Gupta, R.
    Wells, C. D.
    Hittel, N.
    Hafkin, J.
    Geiter, L. J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S33 - S37
  • [5] Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review
    Nugraha, Rhea Veda
    Yunivita, Vycke
    Santoso, Prayudi
    Aarnoutse, Rob E.
    Ruslami, Rovina
    SCIENTIA PHARMACEUTICA, 2021, 89 (02)
  • [6] Management of Multidrug-Resistant Tuberculosis
    Daley, Charles L.
    Caminero, Jose A.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 39 (03) : 310 - 324
  • [7] Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?
    Field, Stephen K.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (04) : 170 - 184
  • [8] Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
    Bolhuis, Mathieu S.
    van Altena, Richard
    van Soolingen, Dick
    de Lange, Wiel C. M.
    Uges, Donald R. A.
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Alffenaar, Jan-Willem C.
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (06) : 1614 - 1621
  • [9] Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Tuberculosis
    Chahine, Elias B.
    Karaoui, Lamis R.
    Mansour, Hanine
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (01) : 107 - 115
  • [10] Multidrug-resistant tuberculosis
    Dheda, Keertan
    Mirzayev, Fuad
    Cirillo, Daniela Maria
    Udwadia, Zarir
    Dooley, Kelly E.
    Chang, Kwok-Chiu
    Omar, Shaheed Vally
    Reuter, Anja
    Perumal, Tahlia
    Horsburgh, C. Robert
    Murray, Megan
    Lange, Christoph
    NATURE REVIEWS DISEASE PRIMERS, 2024, 10 (01)
12345